CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today reported its second quarter of 2017 financial results and corporate highlights.
“The second quarter of 2017 was a very productive period for our company,” said Steve Paul, M.D., president and chief executive officer of Voyager Therapeutics. “Our Parkinson’s disease program continues to advance as we optimize dose and delivery before initiating our pivotal program later this year.
“The second quarter of 2017 was a very productive period for our company,” said Steve Paul, M.D., president and chief executive officer of Voyager Therapeutics. “Our Parkinson’s disease program continues to advance as we optimize dose and delivery before initiating our pivotal program later this year.
